ArticleInternational journal of clinical and experimental pathology2026
Pathological features and prognosis based on microsatellite stability status in colorectal cancer patients: a retrospective analysis.
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is one of the most common and life-threatening intestinal tumors throughout the world. Its incidence and mortality have been going up in recent decades, and more accurate and personalized treatment for CRC are also being developed continuously. Early screening, molecular typing, and risk grouping have become critical for improving patient survival by using sensitive and special biological markers.
methodsWe analyzed the expression of four mismatch repair (MMR) genes, namely MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MutS homolog 6 (MSH6), and PMS1 homolog 2 (PMS2), in CRC and normal tissues using the Tumor, Normal and Metastatic (TNM plot) database. We used the Kaplan-Meier analysis for prognosis, and related pathways were annotated by the Kyoto Encyclopedia of Genes and Genomes. We conducted a retrospective study with 115 CRC patients, who were divided into microsatellite stable (MSS) and microsatellite instability (MSI) groups by immunohistochemistry (IHC). The diagnostic value of MMR markers was assessed through receiver operating characteristic (ROC) curve analysis.
resultsOnline data showed that MMR genes were more highly expressed in CRC than in the normal group (P<0.05). Low expression of these genes was linked to shorter recurrence free survival (RFS, P<0.05), and the related signaling pathways also exert an impact on cell cycle regulation. In clinical samples, loss of MLH1 expression was found in female patients, those aged ≥60 years and lymph node-negative cases (P<0.05). MSI-positive tumors were mostly located in the right-sided colon (P<0.05). The combined model of MSH6 and PMS2 had the highest area under the curve (AUC) of 0.981 (95% confidence interval (CI): 0.936-0.997, P<0.001).
conclusionCombined detection of MSH6 and PMS2 serves as a reliable biomarker for determining the microsatellite status in CRC. This study provides a basis for the precise diagnosis and targeted therapy of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.